
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
Keywords: Respiratory syncytial virus (RSV); Nanoparticle vaccine; Fusion protein (F protein); Microneutralization; Palivizumab; Competitive ELISA; Anti-F IgG; Aluminum phosphate; SF9 insect cell